openPR Logo
Press release

Gonorrhea Therapeutics Market Assessment & Development Forecast Highlighting Prominent Drivers during 2019 to 2029 | Key Players are Bayer AG, GlaxoSmithKline Plc., Baxter International Inc., etc.

08-02-2019 09:22 AM CET | Health & Medicine

Press release from: Fact.MR

Gonorrhea Therapeutics Market Assessment & Development

In order to dissert the market scenario prevailing across the gonorrhea therapeutics market sector, FactMR has evenly presented a comprehensive analysis report on gonorrhea therapeutics market to its extensive online repository. With all vital market facets enclosed into this single assessment, readers can learn about different market drivers, opportunities and trends which are likely to influence the overall market space for the gonorrhea therapeutics market in the coming years. In addition, factors such as market size, Y-o-Y growth and revenue share are investigated so as to make this research highly authentic and reliable.

Request for a Free Sample Report of Concerned Market - https://www.factmr.com/connectus/sample?flag=S&rep_id=3761

Gonorrhea Therapeutics Market in Numbers:

The gonorrhea therapeutics market recorded ~3% CAGR during the period, 2014 to 2018. Gonorrhea emerged as a public threat worldwide with increasing prevalence of the antibiotic-resistant strains, which sustained the demand for gonorrhea therapeutics in recent years.
Revenues from gonorrhea therapeutics around the world is estimated at ~US$ 970 Mn in 2019, and record a 4% Y-o-Y over 2018. The gonorrhea therapeutics industry will remain sustained by inclination of the scientific community toward development of alternative therapies and new antibiotics.
North America remains the most attractive market for gonorrhea therapeutics, primarily upheld by growing government initiatives to compact antibiotic resistance. The US government has released a plan to ‘Combat Antibiotic-Resistant Bacteria’ (CARB) that holds opportunistic potential for companies with strong regional presence.
Research on the drug-resistance gonorrhea, which is likely to pave a potential pipeline for future treatment, is likely to favor the gonorrhea therapeutics industry.
Competition Landscape

According to our study, the gonorrhea therapeutics market will remain a fairly fragmented landscape, with a large number of contenders collectively holding relatively greater shares than the frontrunners and competitors in the market. With ~40% market shares, the contenders are competing with product innovations in active therapy areas, targeted drug delivery, and capacity expansion to meet growing demand for therapeutics abreast escalating prevalence of gonorrhea. Frontrunners in the gonorrhea therapeutics market are focusing more on diagnostic tests and services, and R&D dedicated to biosimilars and generics.

The stakeholders in the gonorrhea therapeutics market are more focused on strengthening their distribution in untapped markets, even as entering into strategic partnerships with local distributors to enhance their supplier force and propel sales. Growing prevalence of antibiotic-resistant gonorrhea has meant that the need for new drugs is evident, as a significant chunk of the global demographic falls prey to the Neisseria gonorrhea bacteria annually. Although progress in gonorrhea vaccines has slugged in the past, recent advances allude an uptick, with conserved vaccine antigens that stimulate bactericidal antibodies being recognized.

New drug developments and laser-sharp focus on quick approvals will remain key winning imperatives for stakeholders in the gonorrhea therapeutics market, in turn complementing their brand repositioning strategies. Prospects for the gonorrhea therapeutics market seem bullish, with key players increasingly vying for geographical presence, new drug launches, and stable supply chain logistics.

Key Challenges Faced by Stakeholders in Gonorrhea Therapeutics Market

The advent of new antibiotic-resistant strains continues to impede the prospects of the gonorrhea therapeutics market by making the currently available drugs lose their effectiveness in fighting the bacterium. The insidious nature of gonorrhea, owing to its growing success at evolving to evade the antibiotics prescribed to treat remains a significant pain-point for stakeholders.
The social stigma surrounding open discussions about STD, particularly in underdeveloped and developing countries has been hampering the true potential of the gonorrhea therapeutics market. Due to poor social acceptance of infection in line with the lack of openness and diverse communication regarding sexuality, the adoption of gonorrhea therapeutics is witnessing a restrictive growth.
Paramount Emphasis on Antibiotic R&D to Favor Gains

Antimicrobial resistance (AMR) has become a rapidly growing global public health threat. With AMR making more than 375 million annual new cases of sexually-transmitted infections (STIs) that are stringent to treat, there has emerged a dire need to tackle this upcoming health crisis. The bacteria that causes gonorrhea is particularly prone to drug resistance, and is classed as ‘high priority’ for renewed antibiotic R&D by leading health organizations.

Turning into a global public health concern, in line with the high unmet need for gonorrhea treatment, growing prevalence of this infection has propelled organizations to collaborate and develop a novel treatment in this light. For instance, Entasis Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP) had collaborated to co-develop a new drug zoliflodacin, specifically to treat drug-resistant gonorrhea, while hoping to provide a solution. Zoliflodacin is a new and first-in-class oral antibiotic that inhibits DNA synthesis in a different way than currently approved antibiotics. Zoliflodacin has been awarded fast track status by the FDA for development as oral treatment for gonorrhea infections, which is likely to translate into significant gains for the gonorrhea therapeutics market in the years to come.

Gonorrhea Therapeutics Market – Research Methodology

An authentic methodology and holistic approach lay the base of the actionable information mentioned in the report on gonorrhea therapeutics market. The FactMR study provides detailed information about the growth forecast of gonorrhea therapeutics market, along with an organized breakdown of the factors shaping the dynamics of the market. Thorough primary and secondary has been employed to accumulate and present valuable insights into the projection analysis of gonorrhea therapeutics market. The report on gonorrhea therapeutics market has also passed through several validation tunnels to ensure that that insights covered in the report are exclusive and one of its kind.

Ask Industry Experts about this Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=3761

Contact Us
FactMR
11140 Rockville Pike
Suite 400, Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at: https://insiderstribune.com

About FactMR

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gonorrhea Therapeutics Market Assessment & Development Forecast Highlighting Prominent Drivers during 2019 to 2029 | Key Players are Bayer AG, GlaxoSmithKline Plc., Baxter International Inc., etc. here

News-ID: 1817150 • Views:

More Releases from Fact.MR

Elevators Market to Grow at 11% CAGR, Reaching $270 Billion by 2033
Elevators Market to Grow at 11% CAGR, Reaching $270 Billion by 2033
The international elevators market (エレベーター市場) got to an evaluation of United States $ 95 billion in 2023 as well as is predicted to get to United States $ 270 billion by the end of 2033. This market is anticipated to expand at a substantial CAGR of 11% from 2023 to 2033. The elevators market stands as a crucial cog in the wheel of contemporary facilities, promoting upright mobility in significantly metropolitan
Stone Paper Market Explosive Growth CAGR of 8.0% to Reach $2,096.9 Million by 2033
Stone Paper Market Explosive Growth CAGR of 8.0% to Reach $2,096.9 Million by 20 …
The international stone paper market (ストーンペーパーマーケット) is forecasted to get to an assessment of United States $ 972.6 million by the end of 2023 and also is anticipated to expand at a CAGR of 8.0% to get to United States $ 2,096.9 million by the end of 2033. The stone paper market is experiencing considerable development possibilities driven by raising need from the product packaging as well as publishing markets. Customer
Foliar Fertilizers Market Predicts 4% CAGR, $344 Million Expansion by 2029
Foliar Fertilizers Market Predicts 4% CAGR, $344 Million Expansion by 2029
The worldwide foliar fertilizers market is forecasted to accomplish a 4% ordinary substance yearly development price (CAGR) by the verdict of the projection duration. This development is anticipated to produce an increment chance of United States$ 344 million by the end of 2029. Foliar plant foods supply an useful choice for supplying nutrients to plants as they can be straight related to the fallen leaves. This approach not just improves nutrient
E-Compass Market $11.9 Billion Discovery By 2033 | Fact.MR
E-Compass Market $11.9 Billion Discovery By 2033 | Fact.MR
In 2023, the global E-Compass Market reached a valuation of US$ 2.6 billion, and projections indicate a substantial growth trajectory, with estimates soaring to US$ 11.9 billion by 2033. 𝗚𝗲𝘁 𝗙𝗿𝗲𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝗽𝘆: https://www.factmr.com/connectus/sample?flag=S&rep_id=8417 This remarkable surge in market value is attributed to the anticipated surge in worldwide electronic compass sales, expected to surge at an impressive Compound Annual Growth Rate (CAGR) of 16.5% over the coming decade. The eCompass, an electric

All 5 Releases


More Releases for Gonorrhea

Gonorrhea - Drug Pipeline Landscape, 2022
Gonorrhea is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. Gonorrhea most often affects the urethra, r*ctum or throat. In females, gonorrhea can also infect the cervix. Symptoms of Gonorrhea infection in men include painful urination, pain or swelling in one t*sticle and in women include increased vaginal discharge, painful urination, vaginal bleeding between periods and abdominal or pelvic pain. Diagnosis of Gonorrhea can be done after
Gonorrhea - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Gonorrhea - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea - Pipeline Review, H2 2017, provides an overview of the Gonorrhea (Infectious Disease) pipeline landscape. Gonorrhea is an infection caused by a sexually transmitted bacterium that can infect both males and females. Gonorrhea most often affects
Gonorrhea Testing Market Snapshot by 2017 – 2025
Gonorrhea is one of the very common sexually transmitted disease (STD), which is basically an inflammation on mucous membrane surface caused by microorganism Neisseria gonorrhoeae. The infection can affect both men and women. In women, the infection grows in moist & warmth area of reproductive track including uterus, cervix, and fallopian tube. The infection also grows in mouth, throat, urethra and anus, in both men and women. Most of the
Gonorrhea Diagnostics Market Information - Forecast To 2023
Gonorrhea is a sexually transmitted disease caused by the bacterium Neisseria gonorrhoeae and can affect both genders. It is a common infection, especially among young people aged between 15 years to 24 years. According to the U.S. Centers for Disease Control and Prevention (CDC), gonorrhea is the second most commonly reported disease in the United States affecting approximately 800,000 people each year. In the United Kingdom, about 28,000 cases of
Global Gonorrhea Diagnostics Market Research Report 2017
Global Gonorrhea Diagnostics Industry 2017 Market Overview, Size, Share, Trends, Analysis, Technology, Applications, Growth, Market Status, Demands, Insights, Development, Research and Forecast 2017-2020. A new research report on the global Gonorrhea Diagnostics market offers a 360-degree overview of it. The report discusses the market in significant details and elucidates all aspects of the global Gonorrhea Diagnostics market likely to impact its growth trajectory in the upcoming years. Major market stimulants and
Global Gonorrhea Diagnostics Market Research Report 2017
This report studies Gonorrhea Diagnostics in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering Abbott Laboratories Beckman Coulter Roche Diagnostics Siemens Agilent Technologies Alere Becton Dickinson and Company F.Hoffmann-La Roche AG Tosoh Corporation PerkinElmer,Inc Bio-Rad Request Sample Report: http://www.reportbazzar.com/request-sample/?pid=888233&ptitle=Global+Gonorrhea+Diagnostics+Market+Research+Report+2017&req=Sample Cepheid Diamedix Kyowa Medex Lonza Mackay Life Sciences Nihon Kohden Ortho Clinical Diagnostics Polymedco Qiagen SDIX Sequenom Sienco Sysmex Takara Bio Market Segment by Regions, this report splits Global into several key Regions, with production,